Quantitative Comparison of the Efficacies of 5 First‐Line Drugs for Primary Restless Leg Syndrome.
- Published in:
- Journal of Clinical Pharmacology, 2019, v. 59, n. 9, p. 1177, doi. 10.1002/jcph.1426
- By:
- Publication type:
- Article
Works matching IS 00912700 AND DT 2019 AND VI 59 AND IP 9
Results: 16
1
2
Inverse Association of Fibrates and Liver Cancer: A Population‐Based Case‐Control Study in Taiwan.
- Published in:
- Journal of Clinical Pharmacology, 2019, v. 59, n. 9, p. 1170, doi. 10.1002/jcph.1419
- By:
- Publication type:
- Article
3
Evaluating the Clinical Impact of Formulation Variability: A Metoprolol Extended‐Release Case Study.
- Published in:
- Journal of Clinical Pharmacology, 2019, v. 59, n. 9, p. 1266, doi. 10.1002/jcph.1433
- By:
- Publication type:
- Article
4
Pharmacogenetic Analysis of OATP1B1, UGT1A1, and BCRP Variants in Relation to the Pharmacokinetics of Letermovir in Previously Conducted Clinical Studies.
- Published in:
- Journal of Clinical Pharmacology, 2019, v. 59, n. 9, p. 1236, doi. 10.1002/jcph.1420
- By:
- Publication type:
- Article
5
Decision Science for Generic Drug Development and Review.
- Published in:
- Journal of Clinical Pharmacology, 2019, v. 59, n. 9, p. 1249, doi. 10.1002/jcph.929
- By:
- Publication type:
- Article
6
Real‐World Data Approaches for Early Detection of Potential Safety and Effectiveness Signals for Generic Substitution: A Metoprolol Extended‐Release Case Study.
- Published in:
- Journal of Clinical Pharmacology, 2019, v. 59, n. 9, p. 1275, doi. 10.1002/jcph.1436
- By:
- Publication type:
- Article
7
An Integrated Bioinformatics and Quantitative Modeling Approach to Investigate Potential Claims of Oral Generic Drug Product Bioinequivalence: Introduction.
- Published in:
- Journal of Clinical Pharmacology, 2019, v. 59, n. 9, p. 1245, doi. 10.1002/jcph.901
- By:
- Publication type:
- Article
8
Issue Information.
- Published in:
- 2019
- Publication type:
- Table of Contents
9
Physiologically Based Pharmacokinetic Modeling to Evaluate Formulation Factors Influencing Bioequivalence of Metoprolol Extended‐Release Products.
- Published in:
- 2019
- Publication type:
- Correction Notice
10
Loperamide: A Readily Available but Dangerous Opioid Substitute.
- Published in:
- Journal of Clinical Pharmacology, 2019, v. 59, n. 9, p. 1165, doi. 10.1002/jcph.1449
- By:
- Publication type:
- Article
11
An Integrated Population Pharmacokinetic Model Versus Individual Models of Depatuxizumab Mafodotin, an Anti‐EGFR Antibody Drug Conjugate, in Patients With Solid Tumors Likely to Overexpress EGFR.
- Published in:
- Journal of Clinical Pharmacology, 2019, v. 59, n. 9, p. 1225, doi. 10.1002/jcph.1418
- By:
- Publication type:
- Article
12
Population Pharmacokinetics of Pemetrexed in Adult Non–Small Cell Lung Cancer in Indian Patients.
- Published in:
- Journal of Clinical Pharmacology, 2019, v. 59, n. 9, p. 1216, doi. 10.1002/jcph.1417
- By:
- Publication type:
- Article
13
Pharmacokinetics of the Investigational Aurora A Kinase Inhibitor Alisertib in Adult Patients With Advanced Solid Tumors or Relapsed/Refractory Lymphoma With Varying Degrees of Hepatic Dysfunction.
- Published in:
- Journal of Clinical Pharmacology, 2019, v. 59, n. 9, p. 1204, doi. 10.1002/jcph.1416
- By:
- Publication type:
- Article
14
A Phase 1 Mass Balance Study of <sup>14</sup>C‐Labeled Talazoparib in Patients With Advanced Solid Tumors.
- Published in:
- Journal of Clinical Pharmacology, 2019, v. 59, n. 9, p. 1195, doi. 10.1002/jcph.1415
- By:
- Publication type:
- Article
15
Characterization of the Effect of Hepatic Impairment on Upadacitinib Pharmacokinetics.
- Published in:
- Journal of Clinical Pharmacology, 2019, v. 59, n. 9, p. 1188, doi. 10.1002/jcph.1414
- By:
- Publication type:
- Article
16
Physiologically Based Pharmacokinetic Modeling to Evaluate Formulation Factors Influencing Bioequivalence of Metoprolol Extended‐Release Products.
- Published in:
- Journal of Clinical Pharmacology, 2019, v. 59, n. 9, p. 1252, doi. 10.1002/jcph.1017
- By:
- Publication type:
- Article